Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. 1984

B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate

Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to treatment with aminoglutethimide plus cortisone acetate. All had relapsed from or failed to respond to primary endocrine treatment with orchidectomy or stilboestrol. Nineteen patients (48%) showed subjective response, in most cases relief of bone pain. Side effects limited treatment in only 3 patients. We conclude that aminoglutethimide plus cortisone acetate is a useful addition to the treatment available for this difficult group of patients. The mechanism by which this treatment has a beneficial effect remains unclear.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003348 Cortisone A naturally occurring glucocorticoid that has been used in replacement therapy for ADRENAL INSUFFICIENCY and as an anti-inflammatory agent. Cortisone itself is inactive; it is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726) 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate,Adreson,Cortisone Acetate,Cortone Acetate
D003687 Dehydroepiandrosterone A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. Dehydroisoandrosterone,Prasterone,5-Androsten-3-beta-hydroxy-17-one,5-Androsten-3-ol-17-one,Androstenolone,DHEA,Prasterone, 3 alpha-Isomer,5 Androsten 3 beta hydroxy 17 one,5 Androsten 3 ol 17 one,Prasterone, 3 alpha Isomer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000616 Aminoglutethimide An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER. Cytadren,Orimeten
D000735 Androstenedione A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL. 4-Androstene-3,17-dione,delta-4-Androstenedione,4 Androstene 3,17 dione,delta 4 Androstenedione

Related Publications

B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1987, Progress in clinical and biological research,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1985, Der Urologe. Ausg. A,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
April 1987, British journal of urology,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1988, European urology,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1980, Lancet (London, England),
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
April 1985, European journal of cancer & clinical oncology,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1993, Anticancer research,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1982, The Medical journal of Australia,
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
January 1990, European journal of cancer (Oxford, England : 1990),
B A Ponder, and R J Shearer, and R D Pocock, and J Miller, and D Easton, and C E Chilvers, and M Dowsett, and S L Jeffcoate
February 1976, The Journal of urology,
Copied contents to your clipboard!